Ampyra for Optic Neuritis in Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Multiple SclerosisOptic Neuritis
Interventions
DRUG

Dalfampridine/Placebo

Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.

DRUG

Placebo/Dalfampridine

Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.

Trial Locations (1)

63110

Washington University (John L. Trotter MS Center), St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Acorda Therapeutics

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01337986 - Ampyra for Optic Neuritis in Multiple Sclerosis | Biotech Hunter | Biotech Hunter